Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase ...
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very ...
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor ...
PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT ™ plus immune ...
Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) ...
BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly ...
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Accessibility Tools
